CryoLife, Inc. Receives Line of Credit for up to $15 Million; Strengthens the Company's Financial Position

ATLANTA, Feb 09, 2005 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced it has entered into a credit agreement with Wells Fargo Foothill, part of Wells Fargo & Company (NYSE: WFC), providing for a revolving credit facility in an aggregate amount equal to the lesser of $15.0 million or a specified borrowing base. The credit agreement expires in February 2008, at which time the outstanding principal balance will be due.

Amounts borrowed are secured by substantially all of the assets of CryoLife and its subsidiaries. The credit agreement includes various covenants such as minimum EBITDA and cash availability, customary conditions on incurring new indebtedness and limitations on cash dividends.

Steven G. Anderson, President and Chief Executive Officer of CryoLife, Inc., noted, "This credit facility is available for a period of three years and is expected to be used for general corporate purposes. Our strengthened financial position, improved tissue processing procedures, continued BioGlue sales growth, and recently announced AATB accreditation are all key factors that will drive our success in 2005."

About CryoLife

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiovascular and vascular surgeries throughout the United States and Canada. The Company's BioGlue Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels and is CE marked in the European Community and approved in Canada for use in soft tissue repair and approved in Australia for use in vascular and pulmonary sealing and repair. The Company also manufactures the SG Model #100 vascular graft, which is CE marked for distribution within the European Community.

About Wells Fargo Foothill

Wells Fargo Foothill is a leading provider of senior secured financing to middle-market companies across the United States and Canada. It is part of Wells Fargo & Company, a diversified financial services company with $428 billion in assets, providing banking, insurance, investments, mortgage and consumer finance to more than 23 million customers from more than 6,000 stores and the Internet (wellsfargo.com) across North America and elsewhere internationally. Wells Fargo Bank, N.A. is the only "Aaa"-rated bank in the United States. For more information, visit Wells Fargo Foothill on the Internet at www.wffoothill.com .

Statements made in this press release that look forward in time or that express management's beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. These risks and uncertainties include that the additional funding provided by the new credit agreement, improved tissue processing procedures, continued BioGlue sales growth, and recently announced AATB accreditation will not make a positive contribution to CryoLife's results of operations, financial position or business success in 2005, that the Company's revenues and expenses may not meet its expectations, that demand for CryoLife preserved tissues may not improve, the possibility that the FDA could impose additional restrictions on CryoLife's operations or require a recall, that the Company may not have sufficient borrowing or other capital availability to fund its business, that present and future litigation may be resolved only by substantial payments by the Company in excess of available insurance coverage, the possibility of severe decreases in the Company's revenues and working capital, that to the extent the Company does not have sufficient resources, it may be forced to cease operations or seek protection under applicable bankruptcy laws, changes in laws and regulations applicable to CryoLife and other risk factors detailed in CryoLife's Securities and Exchange Commission filings, including CryoLife's Form 10-K filing for the year ended December 31, 2003, and the Company's other SEC filings. The Company does not undertake to update its forward-looking statements.

For additional information about the company, visit CryoLife's website: www.cryolife.com .

Contact: Joseph T. Schepers

Vice President, Corporate Communications

(770) 419-3355

SOURCE CryoLife, Inc.